NasdaqGS:OMCLMedical Equipment
Assessing Omnicell (OMCL) Valuation As ANiGENT Deal Accelerates Shift To Software And Services
Omnicell (OMCL) is drawing fresh investor attention after its shift toward software and services was underscored by the ANiGENT acquisition, a move that centers on drug diversion detection and recurring revenue potential.
See our latest analysis for Omnicell.
While Omnicell’s latest software-focused move has caught attention, the share price tells a mixed story, with a 90 day share price return of 13.79% contrasting with a 5 year total shareholder return decline of 66.95%, suggesting recent...